ArticleScientific reports2025
Effect of defective H2B ubiquitination on the malignancy and repair of DNA double breaks and its significance in lung adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines.International journal of molecular sciences · 2026Article
- Comprehensive Pan-Cancer Analysis Reveals RNF20 as a Candidate Prognostic and Diagnostic Biomarker.Bioinformatics and biology insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related mortality, with a notably low five-year survival rate due to the limited availability of effective treatments. Monoubiquitination of histone H2B at lysine 120(uH2B) exerts a tumor-suppressive effect in cancer through multiple mechanisms, including the regulation of transcriptional activity and DNA damage response. Ring Finger Protein 20 (RNF20), a key E3 ubiquitin ligase, plays a central role in this process. However, the role of RNF20 in lung adenocarcinoma (LUAD) progression is unknown. In this study, the functional characterization of the role and molecular mechanism of LUAD were examined using a series of biological and cellular approaches in vitro and in vivo. Our work shows the expression of uH2B is significantly reduced in LUAD patients and is correlated with prognosis. Similarly, RNF20 expression is also markedly decreased in LUAD. Knockdown of RNF20 promoted the proliferation and migration of A549 cells while simultaneously decreasing uH2B expression. Additionally, RNF20 knockdown impaired the DNA damage repair capacity of LUAD cells. RNF20-silenced A549 cells exhibited heightened sensitivity to both the Cisplatin and PARP inhibitor Olaparib. These findings provide an important foundation for further understanding the molecular mechanisms of lung adenocarcinoma and developing new treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.